Volume 2.36 | Sep 30

Researchers Map Genome of Advanced, Lethal Prostate Cancers and Discover ‘Hypermutations’
A team of researchers has conducted the first comprehensive assessment of every gene in the genome of advanced, lethal prostate cancer. [Press release from Fred Hutchinson Cancer Research Center discussing online prepublication in the Proceedings of the National Academy of Sciences USA] Press Release | Abstract

LABORATORY RESEARCH

HER2 Overcomes PTEN (Loss)-Induced Senescence to Cause Aggressive Prostate Cancer
In this study, scientists show that patients who develop prostate tumors with low levels of PTEN and high levels of HER2/3 have a poor prognosis. [Proc Natl Acad Sci USA] Abstract

Hic-5 Controls BMP4 Responses in Prostate Cancer Cells through Interacting with Smads 1, 5 and 8
Here, researchers report that hydrogen peroxide-inducible clone-5 (Hic-5) binds to Smads 1, 5 and 8, and represses bone morphogenetic protein signaling responses. [Oncogene] Abstract

Lysophosphatidic Acid and Sphingosine-1-Phosphate Promote Morphogenesis and Block Invasion of Prostate Cancer Cells in Three-Dimensional Organotypic Models
This study assessed the role of lipid metabolites on epithelial maturation. [Oncogene] Abstract

Polyphenol-Rich Sweet Potato Greens Extract Inhibits Proliferation and Induces Apoptosis in Prostate Cancer Cells In Vitro and In Vivo
This is the first report to demonstrate the in vitro and in vivo anticancer activity of sweet potato greens in prostate cancer. [Carcinogenesis] Abstract

Reversal of Epigenetic Silencing of AP-2Alpha Results in Increased Zinc Uptake in DU-145 and LNCaP Prostate Cancer Cells
The aim of this work was to assess the involvement of epigenetic processes in the disruption of zinc uptake homeostasis in prostate adenocarcinoma. [Carcinogenesis] Abstract

Upregulated FGFR1 Expression Is Associated with the Transition of Hormone-Naive to Castrate-Resistant Prostate Cancer
To gain a better insight into the molecular signaling cascades involved in clinical castrate-resistant prostate cancer, scientists performed gene expression profiling using the Illumina DASL assay and studied matched hormone-naive and castrate resistant prostate tumors (n=10 pairs). [Br J Cancer] Abstract

CLINICAL RESEARCH

Optimal Prostate-Specific Antigen Screening Interval for Prostate Cancer
The purpose of this study is to identify the optimal interval for repeat prostate-specific antigen testing to screen for prostate cancer in healthy adults. [Annals Oncol] Abstract

Peripheral Blood Reverse Transcription PCR Assay for Prostate Stem Cell Antigen Correlates with Androgen-Independent Progression in Advanced Prostate Cancer
This study is to evaluate the association between peripheral blood prostate stem cell antigen status and androgen-independent progression in a cohort of advanced prostate cancer patients under androgen deprivation therapy. [Int J Cancer] Abstract

Inflammation, Focal Atrophic Lesions, and Prostatic Intraepithelial Neoplasia with Respect to Risk of Lethal Prostate Cancer
Data show that prostatic intraepithelial neoplasia, and perhaps presence of moderate or severe chronic inflammation, may have prognostic significance for prostate cancer. [Cancer Epidemiol Biomarkers Prev] Abstract | Press Release

2 New Cost-Effective Ways to Predict Prostate Cancer
Two new risk indicators for prostate cancer were unveiled at the 2011 European Multidisciplinary Cancer Congress. [Press release from ScienceDaily discussing research presented at the 2011 European Multidisciplinary Cancer Congress, Stockholm] Press Release

Positive Phase III Data on Bayer’s Investigational Drug Alpharadin Show Significant Increase in Overall Survival
Bayer HealthCare Pharmaceuticals announced positive data on its investigational drug Alpharadin (radium-223 chloride) from the Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial. [Press release from Bayer HealthCare Pharmaceuticals discussing research presented at the 2011 European Multidisciplinary Cancer Congress, Stockholm] Press Release

Aeterna Zentaris Announces Interim Data for its Phase I/II Trial with AEZS-108 in Prostate Cancer at ESMO Congress
Aeterna Zentaris Inc. announced positive interim data for the Phase I portion of its ongoing Phase I/II study in castration and taxane-resistant prostate cancer with its targeted cytotoxic luteinizing hormone releasing hormone analog, AEZS-108. [Press release from Aeterna Zentaris Inc. discussing research presented at the European Society of Medical Oncology (ESMO) Congress, Stockholm] Press Release

Shorter Radiation Course for Prostate Cancer Is Effective in Long-Term Follow-Up
A shorter course of radiation treatment that delivers higher doses of radiation per day in fewer days (hypofractionation) is as effective in decreasing intermediate to high-risk prostate cancer from returning as conventional radiation therapy at five years after treatment, according to a randomized trial. [Press release from ScienceDaily discussing research presented at the 53rd Annual Meeting of the American Society for Radiation Oncology, Miami] Press Release

Health Discovery Corporation Announces Issuance of First Patent Covering Prostate Cancer Biomarkers
Health Discovery Corporation (HDC) announced that the United States Patent and Trademark Office has issued the first of what the Company expects to be several patents covering methods to screen for the presence of prostate cancer using genomic biomarkers that were identified by HDC researchers using the Company’s patented RFE-SVM algorithm. [Health Discovery Corporation] Press Release

Cleveland BioLabs and RUSNANO Enter Into Agreement to Form New Joint Venture to Develop Innovative Compounds for Cancer and Infectious Disease
Cleveland BioLabs, Inc. (CBLI) announced that it has entered into an agreement with RUSNANO to provide funding for CBLI’s new subsidiary, Panacela Labs, Inc., which will develop a portfolio of new preclinical drug candidates. [Cleveland BioLabs, Inc.] Press Release

International Society for Cellular Therapy (ISCT) Leads Roundtable with Major US Payors, Healthcare Providers and Industry to Initiate a Collaboration to Address Cell Therapy Product Reimbursement
In keeping with its mission to drive the commercialization of cell therapy products and advance global patient access, ISCT hosted its second event this year in its Commercial Development Series, this time focusing on the timely issue of reimbursement for cell therapy and regenerative medicine products in the US market. [International Society for Cellular Therapy, United States] Press Release

President Obama Honors Outstanding Early-Career Scientists
President Obama named 94 researchers as recipients of the Presidential Early Career Awards for Scientists and Engineers, the highest honor bestowed by the United States government on science and engineering professionals in the early stages of their independent research careers. [President Barack Obama, United States] Press Release

NICE Consults on a New Treatment for Prostate Cancer
The National Institute of Clinical Health and Excellence (NICE) has issued new draft guidance not recommending the use of cabazitaxel (Jevtana, Sanofi), in combination with prednisone or prednisolone as a second line treatment for prostate cancer. [National Institute of Clinical Health and Excellence, United Kingdom] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Scientist (iPSC) (STEMCELL Technologies)

Contract Assay Service Technologist (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies) 

Postdoctoral Fellow – Cancer Genome Project (Wellcome Trust Sanger Institute)

Research Associate – Development (Precision Therapeutics, Inc.) 

Postdoctoral Fellow in Prostate Cancer Research (University of Texas Southwestern Medical Center)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!